Announcements
- NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
- NANOBIOTIX annonce une présentation de nouvelles données et du programme d’immunothérapie de Phase 1 lors de la réunion annuelle 2024 de l’American Society for Clinical Oncology (ASCO) suivi d’une conférence téléphonique et webcast
- NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
- NANOBIOTIX participera à la conférence Jefferies Global Healthcare
- NANOBIOTIX fait le point sur ses résultats financiers et opérationnels du premier trimestre 2024
- NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
- Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
- Nanobiotix annonce des avancees de la collaboration globale de developpement autour de NBTXR3 refletant son pipeline robuste et son approche de croissance sur le long terme
- Voting Rights and Shares Capital of the Company
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
More ▼
Key statistics
On Thursday, Nanobiotix SA (5NRA:BER) closed at 5.75, 36.26% above the 52 week low of 4.22 set on Jun 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 5.75 |
Average volume | -- |
---|---|
Shares outstanding | 47.13m |
Free float | 40.40m |
P/E (TTM) | -- |
Market cap | 331.35m USD |
EPS (TTM) | -1.19 USD |
Data delayed at least 15 minutes, as of Nov 02 2023.
More ▼